Genentech has reported positive findings from the Phase III IMbrave050 trial of Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) to treat patients with hepatocellular carcinoma (HCC), a type of adjuvant liver cancer.

The results showed that the therapy combination minimised the risk of cancer returning by 28% in comparison with active surveillance at 17.4 months of median follow-up period.

The independent review facility RFS hazard ratio data were also found to be generally consistent across clinical subgroups of the trial.  

At 7%, overall survival (OS), a major secondary endpoint, was reported immature at the time of data evaluation.

The safety data for the combination of Tecentriq and Avastin were in line with the well-established safety profile of each of the treatment and with the underlying disease.

The therapy combination was the first treatment in over a decade to significantly advance OS over current standard of care, revealed the IMbrave150 trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Genentech chief medical officer and global product development head Levi Garraway said: “Four out of five people with HCC who receive surgery with curative intent may still see their cancer return.

“Thus, an urgent need exists for adjuvant treatments to prevent early recurrence and improve survival rates.

“With Tecentriq plus Avastin already a standard of care in unresectable HCC, we are pleased with the potential of these results and look forward to seeing more mature data.”

With the IMbrave150 trial, Genentech aims to help change and improve fundamental treatment results for liver cancer patients.

The global, multicentre, open-label, randomised trial has been designed to assess the efficacy and safety of adjuvant Tecentriq and Avastin combination, in comparison with active surveillance, to treat HCC patients who are at high risk of recurrence following surgical resection or ablation with curative intent.